Opioid and Benzodiazepine Use in End-stage Renal Disease: a Systematic Review

Overview

Journal Clin J Am Soc Nephrol

Specialty Nephrology

Date 2010 Nov 13

PMID 21071517

Citations 31

Authors

Ahraaz Wyne

Raman Rai

Meaghan Cuerden

William F Clark

Rita S Suri

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Chronic pain and psychiatric disorders are common in dialysis patients, but the extent to which opioids and benzodiazepines are used is unclear. We conducted a systematic review to determine the: (1) prevalence of opioid and benzodiazepine use among dialysis patients; (2) reasons for use; (3) effectiveness of symptom control; and (4) incidence of adverse events.

Design, Setting, Participants, & Measurements: Two authors reviewed all relevant citations in MEDLINE/EMBASE/CINAHL/BIOSIS Previews/Cochrane and hand-searched bibliographies. Studies after 1990 reporting prevalence estimates for opioid and/or benzodiazepine use in ≥50 dialysis patients were included.

Results: We identified 15 studies from 12 countries over 1995 to 2006. Sample size ranged from 75 to 12,782. Prevalence of opioid and benzodiazepine use was variable, ranging from 5 to 36% (95% CI, 4.1 to 45.5%; n=10) and 8 to 26% (95% CI, 7.1 to 27.3%; n=9), respectively. Prevalence was positively correlated with years on dialysis. Five studies reported on the same cohorts but gave different prevalence estimates. One study verified medication use through patient interviews. Reasons for use were reported in one study. Effectiveness of pain control varied from 17 to 38%, and 72 to 84% of patients with significant pain had no analgesia (n=2). No study rigorously examined for adverse events.

Conclusions: The prevalence of opioid and benzodiazepine use in dialysis patients is highly variable between centers. Further information is needed regarding the appropriateness of these prescriptions, adequacy of symptom control, and incidence of adverse effects in this population.

Citing Articles

Prescription and Dispensation of QT-Prolonging Medications in Individuals Receiving Hemodialysis.

Wang V, Wang C, Assimon M, Pun P, Winkelmayer W, Flythe J JAMA Netw Open. 2024; 7(4):e248732.

PMID: 38687480 PMC: 11061769. DOI: 10.1001/jamanetworkopen.2024.8732.

Therapeutic effects of acupuncture therapy for kidney function and common symptoms in patients with chronic kidney disease: a systematic review and meta-analysis.

Liu S, Zhang F, Bai Y, Huang L, Zhong Y, Li Y Ren Fail. 2024; 46(1):2301504.

PMID: 38189090 PMC: 10776068. DOI: 10.1080/0886022X.2023.2301504.

Mindfulness-based intervention for benzodiazepine deprescription in hemodialysis patients with anxiety and depressive symptoms.

Garel N, Rigas C, Mona Ben Mrad , Bodenstein K, Joober R, Sekhon H J Psychiatry Neurosci. 2023; 48(3):E149-E150.

PMID: 37172961 PMC: 10185346. DOI: 10.1503/jpn.220216.

Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study.

Kliuk-Ben Bassat O, Schechter M, Ashtamker N, Yanuv I, Rozenberg A, Hirshberg B Clin Kidney J. 2023; 16(4):701-710.

PMID: 37007688 PMC: 10061437. DOI: 10.1093/ckj/sfac275.

Acceptability and feasibility of fecal microBIOME and serum metabolite sample collection in people with end-stage kidney disease and pain being treated with HemoDialysis: A pilot study (BIOME-HDp).

Lockwood M, Fischer M, Silva K, Contreras B, Zamora G, Goldstein A Contemp Clin Trials Commun. 2022; 29:100995.

PMID: 36105265 PMC: 9464895. DOI: 10.1016/j.conctc.2022.100995.

References

Lagnaoui R, Depont F, Fourrier A, Abouelfath A, Begaud B, Verdoux H . Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol. 2004; 60(7):523-9. DOI: 10.1007/s00228-004-0808-2. View

Chan G, Matzke G . Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm. 1987; 21(10):773-83. DOI: 10.1177/106002808702101001. View

Carreon M, Fried L, Palevsky P, Kimmel P, Arnold R, Weisbord S . Clinical correlates and treatment of bone/joint pain and difficulty with sexual arousal in patients on maintenance hemodialysis. Hemodial Int. 2008; 12(2):268-74. DOI: 10.1111/j.1542-4758.2008.00264.x. View

Clark J . Chronic pain prevalence and analgesic prescribing in a general medical population. J Pain Symptom Manage. 2002; 23(2):131-7. DOI: 10.1016/s0885-3924(01)00396-7. View

Newcombe R . Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17(8):857-72. DOI: 10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e. View

Henrich W, Agodoa L, Barrett B, Bennett W, Blantz R, BUCKALEW Jr V . Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis. 1996; 27(1):162-5. DOI: 10.1016/s0272-6386(96)90046-3. View

Williams R, Sampson T, Kalilani L, Wurzelmann J, Janning S . Epidemiology of opioid pharmacy claims in the United States. J Opioid Manag. 2008; 4(3):145-52. DOI: 10.5055/jom.2008.0019. View

Unruh M, Buysse D, Dew M, Evans I, Wu A, Fink N . Sleep quality and its correlates in the first year of dialysis. Clin J Am Soc Nephrol. 2007; 1(4):802-10. DOI: 10.2215/CJN.00710206. View

Bailie G, Mason N, Bragg-Gresham J, Gillespie B, Young E . Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for underprescription. Kidney Int. 2004; 65(6):2419-25. DOI: 10.1111/j.1523-1755.2004.00658.x. View

10.

Davison S . Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis. 2003; 42(6):1239-47. DOI: 10.1053/j.ajkd.2003.08.025. View

11.

Launay-Vacher V, Karie S, Fau J, Izzedine H, Deray G . Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J Pain. 2005; 6(3):137-48. DOI: 10.1016/j.jpain.2004.11.009. View

12.

Desmet C, Beguin C, Swine C, Jadoul M . Falls in hemodialysis patients: prospective study of incidence, risk factors, and complications. Am J Kidney Dis. 2005; 45(1):148-53. DOI: 10.1053/j.ajkd.2004.09.027. View

13.

Manley H, Bailie G, Grabe D . Comparing medication use in two hemodialysis units against national dialysis databases. Am J Health Syst Pharm. 2000; 57(9):902-6. DOI: 10.1093/ajhp/57.9.902. View

14.

Valderrabano F, Jofre R, Lopez-Gomez J . Quality of life in end-stage renal disease patients. Am J Kidney Dis. 2001; 38(3):443-64. DOI: 10.1053/ajkd.2001.26824. View

15.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

16.

Weisbord S, Shields A, Mor M, Sevick M, Homer M, Peternel J . Methodology of a randomized clinical trial of symptom management strategies in patients receiving chronic hemodialysis: the SMILE study. Contemp Clin Trials. 2010; 31(5):491-7. DOI: 10.1016/j.cct.2010.06.005. View

17.

Merkus M, Jager K, Dekker F, Boeschoten E, Stevens P, Krediet R . Quality of life in patients on chronic dialysis: self-assessment 3 months after the start of treatment. The Necosad Study Group. Am J Kidney Dis. 1997; 29(4):584-92. DOI: 10.1016/s0272-6386(97)90342-5. View

18.

Manley H, Drayer D, McClaran M, Bender W, Muther R . Drug record discrepancies in an outpatient electronic medical record: frequency, type, and potential impact on patient care at a hemodialysis center. Pharmacotherapy. 2003; 23(2):231-9. DOI: 10.1592/phco.23.2.231.32079. View

19.

. Medication use among dialysis patients in the DMMS. United States Renal Data System. Dialysis Morbidity and Mortality Study. Am J Kidney Dis. 1998; 32(2 Suppl 1):S60-8. DOI: 10.1053/ajkd.1998.v32.pm9713408. View

20.

Portenoy R . Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage. 1996; 11(4):203-17. DOI: 10.1016/0885-3924(95)00187-5. View